Evidence map›Paper›PMID 42206104›Full record

ArticleOpen life sciences2026

Alpha-1-antichymotrypsin: a potential inducer for epithelial-mesenchymal transition in lupus nephritis.

Xiaoyan Huang, Cuijuan Zhang, Ming Yang, Xiaoshu Dong, Hui Zhang, Xingjiao Liu, Yi Jiang, Yongfei Wang, Yushuang Wei, Bing Yuan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoyan HuangDepartment of Nephrology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
Cuijuan ZhangDepartment of Cardiovascular Surgery, First Center of 301 Chinese PLA General Hospital, Beijing, 100853, China.
Ming YangDepartment of Otolaryngology, Shenzhen People's Hospital, Shenzhen 518020, China.
Xiaoshu DongDepartment of Rheumatology and Immunology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, 518055, China.ORCID https://orcid.org/0009-0001-6712-9357
Hui ZhangDepartment of Laboratory Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, 518020, China.
Xingjiao LiuDepartment of Rheumatology and Immunology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, 518055, China.
Yi JiangDepartment of Rheumatology and Immunology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, 518055, China.
Yongfei WangSchool of Medicine and Warshel Institute for Computational Biology, Chinese University of Hong Kong, Shenzhen, Guangdong, China.ORCID https://orcid.org/0000-0002-1260-6291
Yushuang WeiSongshan Lake Materials Laboratory, Dongguan, Guangdong Province, 523808, China.ORCID https://orcid.org/0009-0002-5660-1609
Bing YuanSongshan Lake Materials Laboratory, Dongguan, Guangdong Province, 523808, China.ORCID https://orcid.org/0000-0001-8418-9274
Meiying WangDepartment of Rheumatology and Immunology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, 518055, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus and represents a major risk factor for mortality. The critical pathological process affecting the renal parenchyma is fibrosis, which ultimately progresses to end-stage kidney disease. Identifying the molecular mediators of fibrosis is crucial for developing novel therapeutic strategies for lupus patients. Herein, we demonstrate that alpha-1-antichymotrypsin (AACT) is a critical inducer of the epithelial-mesenchymal transition (EMT) in HK-2 cells. Immunohistochemical analysis reveal that AACT expression progressively increases with advancing LN class. We next generate AACT knockout (AACT

Indexed as

alpha-1-antichymotrypsinepithelial-mesenchymal transitionlupus nephritisrenal fibrosissystemic lupus erythematosus

Identifiers

PMID42206104
PMCPMC13211319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.